X4 Pharmaceuticals (XFOR)
NASDAQ:XFOR
Want to see XFOR full AI Analyst Report?
XFOR Stock Chart & Stats
$4.29
-$0.07(-10.26%)
At close: 4:00 PM EST
$4.29
-$0.07(-10.26%)
Day’s Range― - ―
52-Week Range$1.35 - $4.83
Previous CloseN/A
Volume769.31K
Average Volume (3M)409.12K
Market Cap
$398.03M
Enterprise Value$242.34M
Total Cash (Recent Filing)$233.72M
Total Debt (Recent Filing)$77.25M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.54
Shares Outstanding94,319,695
10 Day Avg. Volume494,810
30 Day Avg. Volume409,121
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)4.82
P/FCF Ratio-1.91
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue26.88
Enterprise Value/Gross Profit33.84
Enterprise Value/Ebitda-2.70
Forecast
1Y Price Target
$12.00Price Target Upside179.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.75
Revenue Forecast (FY)$9.07M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strengthened Balance SheetMaterial debt reduction and sizable equity (~$168M) improve financial flexibility and optionality over the next 2–6 months. Low leverage reduces refinancing risk, supports funding of R&D or commercialization initiatives, and gives management runway to execute without near-term covenant pressure.
High Gross MarginsSustained high gross margins indicate attractive product economics for mavorixafor and related programs. If revenue scales, these margins provide the basis for eventual operating leverage, supporting long-term profitability assuming fixed costs are controlled and commercial uptake continues.
Governance Continuity And Retention ToolsBoard continuity and an expanded equity incentive plan strengthen governance and the company’s ability to attract and retain scientific and commercial talent critical for late-stage development and commercialization. Stable leadership and retention tools support consistent execution over the medium term.
Bears Say
Persistent Cash Burn And Negative FCFLarge, recurring operating cash outflows imply continued reliance on external financing to fund operations and trials. This persistent cash burn constrains strategic flexibility, increases dilution risk from future financings, and is a multi‑month structural pressure until revenues or cost structure change materially.
Share Issuance / Dilution RiskExpanding the equity incentive pool supports retention but creates a durable dilution vector for shareholders as awards vest or are issued. Continued funding needs plus share-based compensation could meaningfully expand share count over months, reducing per-share economics unless matched by stronger revenue or margins.
Highly Volatile Revenue TrendsLarge swings in revenue indicate commercialization and/or collaboration timing uncertainty, making cash flow and planning unpredictable. This structural volatility increases execution risk for scaling operations, complicates forecasting, and heightens the probability of further financing needs if revenue does not stabilize.
X4 Pharmaceuticals News
XFOR FAQ
What was X4 Pharmaceuticals’s price range in the past 12 months?
X4 Pharmaceuticals lowest stock price was $1.35 and its highest was $4.83 in the past 12 months.
What is X4 Pharmaceuticals’s market cap?
X4 Pharmaceuticals’s market cap is $398.03M.
When is X4 Pharmaceuticals’s upcoming earnings report date?
X4 Pharmaceuticals’s upcoming earnings report date is Oct 29, 2026 which is in 130 days.
How were X4 Pharmaceuticals’s earnings last quarter?
X4 Pharmaceuticals released its earnings results on May 06, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.04.
Is X4 Pharmaceuticals overvalued?
According to Wall Street analysts X4 Pharmaceuticals’s price is currently Undervalued.
Does X4 Pharmaceuticals pay dividends?
X4 Pharmaceuticals does not currently pay dividends.
What is X4 Pharmaceuticals’s EPS estimate?
X4 Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does X4 Pharmaceuticals have?
X4 Pharmaceuticals has 94,319,695 shares outstanding.
What happened to X4 Pharmaceuticals’s price movement after its last earnings report?
X4 Pharmaceuticals reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went up 4.286%.
Which hedge fund is a major shareholder of X4 Pharmaceuticals?
Currently, no hedge funds are holding shares in XFOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
X4 Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (179.72% Upside)
$12.00 (179.72% Upside)
Blogger Sentiment
Bullish
XFOR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 423.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $72.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.1%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.64%
12-Months-Change
Fundamentals
Return on Equity
-94.90%
Trailing 12-Months
Asset Growth
107.89%
Trailing 12-Months
Company Description
X4 Pharmaceuticals
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
XFOR Stock 12 Month Forecast
Average Price Target
$12.00
▲(179.72% Upside)
Technical Analysis
Ownership Overview
0.91% Insiders
16.12% Mutual Funds
65.44% Other Institutional Investors
13.73% Public Companies and
Individual Investors